08.29.23
Lokavant, a clinical trial intelligence platform company, launched a study planning solution driven by proprietary historical trial data from more than 2,000 studies involving more than 14,000 investigators, 12,000 healthcare institutions, and real-world data (RWD) sources.
According to the company, the new solution empowers clinical trial sponsors and contract research organizations (CROs) to accurately identify the right number, location, and mix of sites for key performance and diversity milestones, as well as other feasibility goals for optimum study performance.
For example, Lokavant used five years of data on chronic obstructive pulmonary disease (COPD) to accurately identify the most efficient and inefficient trial sites for future respiratory trials. According to analysis, sponsors and CROs could reduce the number of sites needed for a study by 18% to 36% and still hit patient enrollment targets.
“We are driving an important next step in the evolution of clinical research,” said Andreas Matern, executive vice president of product development at Lokavant. “Lokavant’s new study planning technology is where clinical trials intersect with predictive analytics. With this new solution, our customers gain more precise insights about the potential performance of their clinical trials and sites before it’s too late and too expensive to course correct.”
The new data-powered study planning solution will be available in 4Q23 as a standalone product or add-on module to its clinical trial intelligence platform.
According to the company, the new solution empowers clinical trial sponsors and contract research organizations (CROs) to accurately identify the right number, location, and mix of sites for key performance and diversity milestones, as well as other feasibility goals for optimum study performance.
For example, Lokavant used five years of data on chronic obstructive pulmonary disease (COPD) to accurately identify the most efficient and inefficient trial sites for future respiratory trials. According to analysis, sponsors and CROs could reduce the number of sites needed for a study by 18% to 36% and still hit patient enrollment targets.
“We are driving an important next step in the evolution of clinical research,” said Andreas Matern, executive vice president of product development at Lokavant. “Lokavant’s new study planning technology is where clinical trials intersect with predictive analytics. With this new solution, our customers gain more precise insights about the potential performance of their clinical trials and sites before it’s too late and too expensive to course correct.”
The new data-powered study planning solution will be available in 4Q23 as a standalone product or add-on module to its clinical trial intelligence platform.
